This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (11)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal

Arch Ophthalmol. 1999;117:1400-1402.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THIS ISSUE OF THE ARCHIVES provides information about a promising new treatment for age-related macular degeneration (AMD), the major cause of severe and irreversible vision loss in the United States and in many developed countries. The article,¹ as well as 2 others published in the September issue of the ARCHIVES,^2-3 describes a series of research projects carried out by investigators in North America and Europe to evaluate photodynamic therapy as a treatment for choroidal neovascularization (CNV), the type of late AMD that is the most frequent cause of visual loss to the level of legal blindness and worse.

Miller et al² determined a safe and effective dose of verteporfin to be used as a photosensitizer in the treatment of CNV. Schmidt-Erfurth et al³ provided safety and efficacy data for retreatment of patients whose CNV closed after the initial treatment but then was reperfused within the next several weeks. The Treatment . . . [Full Text of this Article]

RELATED ARTICLE

Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With Verteporfin: One-Year Results of 2 Randomized Clinical Trials—TAP Report 1
Treatment of Age-related Macular Degeneration With Photodynamic Therapy Study Group
Arch Ophthalmol. 1999;117(10):1329-1345.
ABSTRACT | FULL TEXT